Cancer BiologyeBioMedicinePeer-reviewed
A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma
V. Rey, J. Tornin, J. J. Alba-Linares…·R. Rodriguez
This study identifies enasidenib as an effective treatment for IDH2 mutant chondrosarcoma through personalized medicine approaches involving sequencing, cell line models, and in vitro/in vivo testing.
DOI 10.1016/j.ebiom.2024.105090